trial
as of 2026-07-01Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
NCTId NCT04789915
at a glance
Phase 1 · Recruiting
Enrollment 46 (estimated)
Sponsored by Bjorn H. Ebdrup
Primary completion 2025-07-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Recruiting
Enrollment
46 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-05-26
Primary completion
2025-07-01
Eligibility
ALL · 18 Years · 45 Years
Interventions & indications
Sponsors
Bjorn H. EbdrupLead Sponsor
Lundbeck Canada Inc.Collaborator
Danish Research Centre for Magnetic ResonanceCollaborator
Investigators
1
Olga B Baltzersen, MDPrincipal Investigator
Sites
1 total
Glostrup Municipality, Denmark
Facts & assertions
4 sourced
Enrollment
46
Phase
PHASE1
Primary Completion Date
2025-07-01
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
indication
indication
investigator
person